Q-omics provides the consensus-scored RPL7AP71 profile across patient tissues and cancer cell-line models. RPL7AP71 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP71 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RPL7AP71 RNA expression shows 9,361 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRC, and GBM as cancer lineages where RPL7AP71 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP71 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP71 survival associations across molecular data types. RPL7AP71 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP71 RNA expression–survival associations across cancer types. High RPL7AP71 expression shows unfavorable associations in LIHC, PAAD, ACC and CHOL, but favorable associations in UCEC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL7AP71 RNA expression.
This table summarizes RPL7AP71 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP71. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP71 shows lower tumor expression in READ, COAD and HNSC and higher tumor expression in KIRC, PRAD and LIHC. The KIRC box plot shows higher RPL7AP71 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .008).
This table shows molecular features associated with RPL7AP71 in patient tissues and cancer cell lines. In patient samples, RPL7AP71 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
